Vera Therapeutics, Inc.
VERA evidence brief
What we can confirm
- BioSniper Score:
- 5.7 / 10
- Market Cap:
- $2.53B
- Lead Asset:
- trutakna (Approved)
What it means
What to watch
Prepared research question
What matters most for VERA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VERA
Vera Therapeutics (VERA) is a publicly traded biotech company focused on developing atacicept (TRUTAKNA), a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases, with one approved product and a recent Phase III success.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.53B
Cash Runway
—
Lead Asset
trutakna (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 7 clinical trials · 1 FDA decision for Vera Therapeutics, Inc..
Vera Therapeutics (VERA) is a publicly traded biotech company focused on developing atacicept (TRUTAKNA), a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases, with one approved product and a recent Phase III success.
- TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy, showing prevention of disease progression and stabilization of kidney function [news · 2026-09-17].
- Cash & equivalents were $48.9M as of 2026-06-30, with a net loss of -$109.5M and shareholders' equity of $407.8M [sec].
- Accumulated deficit was $881.9M as of December 31, 2025 [sec_mda · 2026-05-07].
- Management plans to seek full FDA approval for TRUTAKNA later in 2026 via a supplemental biologics license application [news · 2026-09-17].
- The company is evaluating atacicept in other autoimmune kidney diseases through the Phase 2 PIONEER trial, with additional results expected in Q4 2026 [sec_mda · 2026-08-10].
What works
- TRUTAKNA (atacicept) successfully met all Phase III endpoints in the ORIGIN 3 trial, demonstrating disease progression prevention and kidney function stabilization with a favorable safety profile [news · 2026-09-17].
- The drug targets both BAFF and APRIL, key cytokines driving IgAN pathophysiology, and is self-administered as a convenient once-weekly autoinjector [sec_mda · 2026-08-10].
- The company has a pipeline-in-a-molecule strategy, exploring atacicept in multiple autoimmune kidney diseases beyond IgAN, including pMN, FSGS, and MCD [sec_mda · 2026-05-07].
What to weigh
- The company has an accumulated deficit of $881.9M as of December 31, 2025, and expects to continue incurring net operating losses for the foreseeable future [sec_mda · 2026-05-07].
- Vera expects to record only limited revenue from product sales in Q3 2026 and will require substantial additional funding to commercialize its lead product and support operations [sec_mda · 2026-08-10].
- The company relies entirely on third-party manufacturers and has no plans to establish its own manufacturing facilities, creating supply chain dependency [sec_mda · 2026-08-10].
- Cash & equivalents of $48.9M as of 2026-06-30 may be limited relative to ongoing R&D and commercialization expenses [sec].
From the filings
Quoted directly from source documents.
TRUTAKNA met all Phase III endpoints
“Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy.”
News · September 17, 2026
Accumulated deficit as of Dec 31, 2025
“accumulated deficit of $881.9 million, compared to $760.9 million as of December 31, 2025.”
SEC MD&A · May 7, 2026
TRUTAKNA targets BAFF and APRIL
“BAFF and APRIL, the two key cytokines that activate B cells and drive IgAN pathophysiology.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2022-11-02 · Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis — Initiation of a Phase 3 trial for atacicept in lupus nephritis, expanding the pipeline beyond IgAN.
- 2023-06-29 · Phase3_Start: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN) — Start of the pivotal Phase 2b/3 ORIGIN trial for atacicept in IgAN, which later reported positive results.
- 2024-12-01 · Phase2_Start: A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept — Long-term extension study for atacicept, providing data on sustained efficacy and safety.
- 2025-04-01 · Trial_Readout: Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. - Atacicept 96-week treatment resulted in sustained reductions in galactose-d — Readout of long-term (96-week) data showing sustained reductions in disease biomarkers.
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash & equivalents of $48.9M as of 2026-06-30 may be insufficient to fund ongoing R&D and commercialization without additional financing [sec].
- Reliance on third-party manufacturing — Vera has no manufacturing facilities and depends on external partners for drug supply, posing operational risk [sec_mda · 2026-08-10].
- Sustained net operating losses — Company expects to continue incurring net losses for the foreseeable future, with accumulated deficit growing to $881.9M as of Dec 2025 [sec_mda · 2026-05-07].
What to watch
- FDA decision on full approval for TRUTAKNA following planned supplemental BLA submission later in 2026 [news · 2026-09-17].
- Additional results from the Phase 2 PIONEER trial expected in Q4 2026, evaluating atacicept in broader IgAN and other autoimmune kidney diseases [sec_mda · 2026-08-10].
- Revenue generation from TRUTAKNA commercial sales, expected to be limited in Q3 2026 [sec_mda · 2026-08-10].
- Company's ability to raise additional capital to fund operations and commercialization [sec_mda · 2026-08-10].
Sources: Catalysts · News · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Vera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.31 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 24, 2026- % of float
- 15.5%
- Days to cover
- 7.5
- Shares short
- 9,764,156
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VERA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vera Therapeutics, Inc.?
Vera Therapeutics (VERA) is a publicly traded biotech company focused on developing atacicept (TRUTAKNA), a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune kidney diseases, with one approved product and a recent Phase III success.
What is Vera Therapeutics, Inc.'s lead drug candidate?
Vera Therapeutics, Inc.'s most advanced tracked candidate is trutakna (Approved).
Who is the CEO of Vera Therapeutics, Inc.?
Dr. Marshall W. Fordyce M.D. is the chief executive officer of Vera Therapeutics, Inc. (VERA).
Where is Vera Therapeutics, Inc. headquartered?
Vera Therapeutics, Inc. (VERA) is headquartered in Brisbane, CA, United States.
What therapeutic areas does Vera Therapeutics, Inc. focus on?
Vera Therapeutics, Inc. develops therapies across Immunology, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.